Ceres Nanosciences Establishes Sixteen Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative
PR95345
MANASSAS, Va. April 6, 2022 /PRNewswire=KYODO JBN/ --
Ceres Nanosciences (Ceres), a privately held company that makes innovative
products to improve life science research and diagnostic testing, is announcing
the establishment of six new wastewater-based epidemiology centers of
excellence. The new centers add to the nine existing centers of excellence
previously announced in November 2021 (
) and to the wastewater testing program in metro-Atlanta that is being run by
Emory University, all supported by an $8.2 million award (
) from the National Institutes of Health (NIH) Rapid Acceleration of
Diagnostics (RADx(R)) initiative.
Logo - https://mma.prnewswire.com/media/1780598/Ceres_Nanosciences_Logo.jpg
These sixteen sites encompass non-profit, university, public health, and
commercial testing labs located in fourteen states, including Arizona,
California, Connecticut, Illinois, Georgia, Kansas, Kentucky, Louisiana,
Maryland, Massachusetts, New York, Texas, West Virginia, and Wisconsin and are
providing wastewater testing services to forty states.
The centers are regularly monitoring wastewater from a wide range of sources,
including from wastewater treatment plants to provide information on overall
virus trends in a county or city; from sewersheds to support decision-making
for public health resource allocation at a neighborhood level; and from
building-level locations like college dorms, skilled nursing facilities,
correctional facilities, K-12 schools, summer camps, and airports.
Each center was selected (
) based on its ability to utilize the expanded capacity to extend services into
underserved and underprivileged communities and is expected to share results
with local and state public health authorities, as well as to submit data to
the CDC National Wastewater Surveillance System (
) (NWSS).
Each center of excellence received the materials and on-site training to
implement an automated Nanotrap(R) particle protocol, which enables same-day
delivery of wastewater testing results for over 100 samples per day. Extracted
nucleic acids from this automated protocol are compatible with multiple nucleic
acid detection methods, including reverse transcription-quantitative polymerase
chain reaction (RT-qPCR), reverse transcription-droplet digital PCR (RT-ddPCR),
and genomic sequencing.
"The wastewater testing capacity that this NIH-funded program has established
nationwide is proving critical for monitoring the rise of new SARS-CoV-2
variants," said Ben Lepene, Chief Technology Officer at Ceres Nanosciences.
"I'm also very excited by the data we are seeing that demonstrate that the same
method can be used to enable wastewater monitoring of a much wider range of
infectious disease, including other viruses, bacteria, and parasites."
Full details are available at https://www.ceresnano.com/press-release-coe16
Press Contact:
Ross M. Dunlap
Ceres Nanosciences, Inc
1.800.615.0418 ext. 202
rdunlap@ceresnano.com
SOURCE Ceres Nanosciences, Inc
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。